Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TSN-1611 by Tyligand Biotechnology (Shanghai) for Colorectal Cancer: Likelihood of Approval
TSN-1611 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase II for Colorectal Cancer. According to GlobalData,...
TSN-1611 by Tyligand Biotechnology (Shanghai) for Pancreatic Cancer: Likelihood of Approval
TSN-1611 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
TSN-1611 by Tyligand Biotechnology (Shanghai) for Solid Tumor: Likelihood of Approval
TSN-1611 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase II for Solid Tumor. According to GlobalData,...
TSN-1611 by Tyligand Biotechnology (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval
TSN-1611 is under clinical development by Tyligand Biotechnology (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer. According...